Overhauling the Food and Drug Administration (FDA)

The Wall Street Journal reports that Sen. Charles Grassley and Rep.
John Dingell are taking the lead in calling for revamping the FDA which is
recognized as being “too cozy with the companies they regulate.”

“The lawmakers say an FDA restructuring should build a much taller wall
between the agency and the industry it regulates. The FDA would gain
authority to recall drugs, which it can’t do today, and to impose
significant fines on drug companies for safety violations. The lawmakers
also want the FDA to inspect generic-drug makers before approving a new
product. Perhaps most importantly, they want the next president to appoint a
tough FDA commissioner completely independent from the industry.”

An indication that there is a groundswell of support for major reform of the
Sen. Arlen Specter (R., Pa.), usually sympathetic to the agency, called the
FDA “a joke.”
Senate Appropriations Chair Herb Kohl (D., Wis.) upbraided Dr. von
Eschenbach after he had to be dragged to join DHHS secretary in a night time
news conference to announce a request to Congress for additional funds for
overseas inspections after the disastrous Chinese heparin blood scandal.

And, even Billy Tauzin, president of the drug industry’s lobby, PhRMA
(Pharmaceutical Research and Manufacturers of America) acknowledged that he
has warned members about what may lie ahead in the way of tighter

“It’s an accumulation of things some companies did over the years. Now it’s
death by a thousand cuts,” he said in an interview. “We gotta stop the

Indeed, as the St. Petersburg Times reported in May, 2007:

Between 1989–1991: 1.56 Percent of newly approved drugs pulled from market;

Between 1997-2000: 5.34 Percent of newly approved drugs pulled from market;

In 1998, the number of complaints to the FDA about clinical drug trial
irregularities = 10;

In 2006, the number of complaints to the FDA about clinical drug trial
irregularities = 350.


AHRP believes that no meaningful reforms are possible until FDA officials
who have been “cozy with companies”– are replaced with independent
professionals the public can trust. The current FDA top brass has lost
public trust–they cannot, therefore, remain in their positions of

Source: Atypical_Antipsychotics Yahoo Group

Thank you Vera for your contribution!

This website may contain some copyrighted material. We reserve the right to reproduce such material under the Copyright Act, Title 17 US Code, Section 107, “Fair Use”, as we believe the public should be informed of such information so they can think for themselves rather than rely on advertisements. We gain no profit from such articles. http://www.copyright.gov/title17/92chap1.html#107


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: